Tumor-associated antigens (Breast cancer) (TAA)

The term refers to a collective group of tumor-associated antigens (TAAs) expressed by allogeneic breast cancer cell lines, most notably the SV-BR-1-GM (Bria-IMT) cell line. Rather than targeting a single molecule, this approach utilizes the broad antigenic profile of whole tumor cells to stimulate a polyvalent immune response against breast cancer [1]. These antigens are presented to the patient's immune system to activate both helper and cytotoxic T-cells, aiming to overcome the limitations of single-target therapies and tumor heterogeneity [2]. The SV-BR-1-GM cell line is specifically engineered to secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to facilitate the recruitment and maturation of dendritic cells at the site of administration [3]. This therapeutic strategy is primarily investigated for patients with advanced or metastatic breast cancer who have failed multiple lines of standard therapy [1][2]. Clinical efficacy is often correlated with the patient's HLA type, as specific HLA matches between the vaccine cell line and the patient may enhance antigen presentation [3].

Other names

Breast cancer antigensAllogeneic tumor antigensPolyvalent breast cancer antigensSV-BR-1-GM antigens

Induction of a polyvalent immune response by presenting a broad spectrum of tumor-associated antigens to the host immune system, typically enhanced by the secretion of GM-CSF from genetically modified allogeneic cells [1][2].